| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on investment in arrowhead pharmaceuticals | NaN | 0 | -17,293 | NaN |
| Non-cash write-off of prepaid deposits | NaN | 0 | 17,041 | NaN |
| Net income (loss) | 330,959 | -282,847 | -430,563 | NaN |
| (gain) loss on debt extinguishment | NaN | 155,475 | -138,613 | NaN |
| Non-cash inventory write-downs for excess and obsolescence | NaN | 165,257 | NaN | NaN |
| Stock-based compensation | 29,399 | 30,016 | 93,380 | NaN |
| In-kind milestone payment to arrowhead pharmaceuticals | NaN | 0 | 50,000 | NaN |
| Depreciation and amortization | 10,594 | 5,253 | 39,268 | NaN |
| Non-cash interest expense | 9,612 | 13,532 | NaN | NaN |
| Reduction in the carrying amounts of the right of use assets | 3,110 | 2,625 | 11,326 | NaN |
| Non-cash termination charges | NaN | 0 | 0 | NaN |
| Change in the fair value of derivatives | NaN | 11,100 | -11,100 | NaN |
| Impairment of strategic investments | NaN | 0 | NaN | NaN |
| Loss on strategic investments | -1,712 | NaN | NaN | NaN |
| Gain from sale of priority review voucher | NaN | 0 | NaN | NaN |
| Accretion of investment discount, net | -530 | -380 | -4,911 | NaN |
| Other | 1,288 | -2,616 | -4,439 | NaN |
| Decrease (increase) in accounts receivable | -3,416 | 2,494 | -206,249 | NaN |
| Decrease in manufacturing-related deposits and prepaids | -43,487 | -11,768 | -67,072 | NaN |
| Increase in inventory | 69,756 | -18,475 | 319,568 | NaN |
| Increase in other assets | 14,547 | -20,286 | 100,070 | NaN |
| Decrease in deferred revenue | -274,916 | 41,858 | 30,193 | NaN |
| Decrease in accounts payable | -210,465 | NaN | NaN | NaN |
| (decrease) increase in accrued expenses | -60,026 | NaN | NaN | NaN |
| Increase (decrease) in accounts payable, accrued expenses, lease liabilities and other liabilities | NaN | 249,616 | -145,347 | NaN |
| (decrease) increase in lease liabilities and other liabilities | -3,444 | NaN | NaN | NaN |
| Net cash used in operating activities | -202,683 | 131,206 | -336,685 | NaN |
| Purchase of available-for-sale securities | 170,197 | 0 | 44,658 | NaN |
| Proceeds from sale of investment in arrowhead pharmaceuticals | NaN | 0 | 174,095 | NaN |
| Maturity and sales of available-for-sale securities | 38,888 | 99,936 | 195,935 | NaN |
| Purchase of property and equipment | 2,081 | 3,591 | 98,381 | NaN |
| Purchase of intangible assets | 1,000 | 138 | 7,738 | NaN |
| Proceeds from sale of priority review voucher | NaN | 0 | NaN | NaN |
| Acquisition of strategic investments | 0 | 0 | -245,819 | NaN |
| Net cash provided by investing activities | -134,390 | 96,207 | -26,566 | NaN |
| Common stock issuance costs | NaN | 110 | 2,276 | NaN |
| Repayment of 2027 notes, including debt extinguishment costs | NaN | 35,085 | 123,333 | NaN |
| Repurchases of common stock, net of excise tax | NaN | 0 | 25,013 | NaN |
| Proceeds from issuance of common stock | NaN | 0 | 20,000 | NaN |
| Debt issuance costs for the august 2025 exchange and december 2025 exchange (defined in note 13) | NaN | 4,273 | 12,787 | NaN |
| Proceeds from exercise of stock options and purchase of stock under the employee stock purchase program | 241 | 308 | 18,395 | NaN |
| Settlement of capped call share options for 2024 notes | NaN | 0 | NaN | NaN |
| Proceeds from borrowings under the revolving credit facility | 250,000 | NaN | NaN | NaN |
| Payment on maturity of 2024 notes | NaN | 0 | NaN | NaN |
| Repayments of borrowings under the revolving credit facility | 250,000 | NaN | NaN | NaN |
| Debt conversion costs for 2024 notes | NaN | 0 | NaN | NaN |
| Payments related to obtaining the revolving credit facility | 0 | 48 | 4,122 | NaN |
| Net cash provided by financing activities | 241 | -39,208 | -129,136 | NaN |
| Decrease in cash, cash equivalents and restricted cash | -336,832 | 188,205 | -492,387 | NaN |
| Restricted cash in other assets | NaN | NaN | NaN | 15,600 |
| Beginning of year | NaN | 1,118,589 | NaN | NaN |
| Cash and cash equivalents | NaN | NaN | NaN | 510,600 |
| Beginning of period | 288,230 | NaN | NaN | NaN |
| End of year | NaN | 814,407 | NaN | NaN |
| End of period | -48,602 | NaN | NaN | 526,177 |
Sarepta Therapeutics, Inc. (SRPT)
Sarepta Therapeutics, Inc. (SRPT)